WebMD Health News
Daniel J. DeNoon
Louise Chang, MD
Aug. 1, 2007 - A program to prevent birth defects from the acne drug Accutane should be more flexible, an FDA advisory panel said today.
Accutane is a powerful drug that works against some of the hardest-to-treat forms of acne. But the drug also causes birth defects. Women who take the drug must take careful steps to avoid pregnancy.
FDA approval of Accutane requires all patients taking the drug to register with the so-called iPledge program. The program is designed to ensure that patients avoid pregnancy, and links prescriptions to pregnancy tests.
Even so, 122 women taking Accutane (or other versions of the drug generically known as isotretinoin) became pregnant during the first year of the program.
The FDA convened an expert panel to review the iPledge program and to make recommendations on how it might be improved.
The panel today voted to make the program more flexible, to take steps to reduce treatment interruptions, and to reduce unnecessary burdens for patients, an FDA spokesperson tells WebMD.
The panel recommended two major changes to the iPledge program:
FDA panel recommendations are not binding, although the agency almost always follows the advice of its panels.
SOURCES: FDA. News release, March of Dimes.
Here are the most recent story comments.View All
© 2015 Ramar Communications |
Site Map |
Privacy Statement |
Copyright & Trademark Notice |
EEO Report |
FCC Public Files |
Closed Captioning |